Indian Phosphate

- Indian Phosphate Limited has not indicated any current or immediate plans for new debt or long-term borrowings. They are currently utilizing only working capital debt and have zero term loans for their Tamil Nadu plant. - The company raised funds through an IPO, which supported the setting up of the Tamil Nadu (Kudlar) plant. - There is no explicit mention of any future equity fundraising in the transcript. - No indication was given of new debt issuance; external credit rating is under renewal with an expectation of improvement. - The management is focusing on completing ongoing projects, like the Labsa plant and fertilizer plant, rather than initiating new fundraising at this time.

- The company is prioritizing the commissioning and operation of its Tamil Nadu Kadlar plant (Labsa plant) in the current financial year, expecting full operations by FY27. - After the Kadlar plant is operational, focus will shift to the Dhule fertilizer plant; however, there is currently no set timeline for its commissioning. - The Dudule sulfuric acid plant was commissioned recently and is operational, contributing to revenues in H1 of the current financial year. - The Dhule plant construction is approximately 60-65% completed, with completion and commissioning expected in the third or fourth quarter of the next financial year (FY27). - IPO proceeds have been primarily utilized for the Tamil Nadu project; remaining funds and resources will be allocated to the Dhule plant once the Tamil Nadu project stabilization is achieved. - No mention of other significant capital or strategic investments beyond these two major projects.

- H1 FY 25-26 revenue increased by ~15% to ₹451 crores versus ₹385 crores in H1 FY 24-25. - EBITA rose by 40% in H1 FY 25-26 compared to the previous year. - Fertilizer segment expected to improve due to favorable government subsidy restoration. - Chemical segment highly diversified, contributing 90% of revenue; expected continued growth with diversification plans. - Tamil Nadu Labsa plant commissioning anticipated in FY 26-27, expected to add significant turnover and revenue. - Sulfur price volatility impacts revenue, but higher sulfur prices have boosted revenue from sulfuric acid. - Sulfuric acid plant capacity utilization currently around 75%, with aggressive sales plans. - Expected commissioning and operationalization of the Kudlar project by Q3 or Q4 FY 26-27, which should positively contribute to revenue. - Overall outlook optimistic with both fertilizer and chemical segments projected to perform better than last financial year.

- The company expects improvement in both top line and bottom line due to the commissioning of the Labsa and sulfuric acid plants by FY27, leading to better integrated operations and cost efficiencies. - EBITA has shown a 40% jump in H1 of current financial year compared to last year, with margins also improving. - Subsidy conditions for fertilizer have become favorable again, positively impacting the fertilizer segment. - Integrated operations in Tamil Nadu with in-house sulfuric acid production and power generation will reduce costs and improve profitability. - EBITA percentage expected to improve further once new plants are fully operational by the last quarter of FY27. - Growth is linked to volatile raw material costs like LAB and sulfur, but management is optimistic due to diversification and government policy support. - Corporate guarantee related project expected to be operational by FY27, potentially releasing associated guarantees and reducing contingent liabilities.

The transcript provided in the PDF does not explicitly mention the current or expected order book or pending orders for Indian Phosphate Limited. However, the discussion highlights: - Focus on the Tamil Nadu (Kudlar) project as top priority using IPO proceeds. - Delay in project commissioning due to delayed statutory permissions like consent to operate. - Expected commissioning of the Tamil Nadu Labsa plant by the last quarter of FY 25-26. - Sulfuric acid plant already operational, contributing revenue in H1 FY 25-26. - Labsa plant operations expected to add to revenue in the current financial year. - No explicit figures or details on order book or pending orders are disclosed during the call. Hence, no concrete data on current or expected order book/pending orders is available from the transcript.